Precigen, Inc. (PGEN)
6.385
-0.81
(-11.26%)
USD |
NASDAQ |
Oct 16, 16:00
6.38
0.00 (0.00%)
After-Hours: 20:00
Precigen Research and Development Expense (Annual) : 40.06M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 40.06M |
| December 31, 2024 | 50.01M |
| December 31, 2023 | 48.61M |
| December 31, 2022 | 47.17M |
| December 31, 2021 | 47.93M |
| December 31, 2020 | 41.64M |
| December 31, 2019 | 66.67M |
| December 31, 2018 | 366.25M |
| Date | Value |
|---|---|
| December 31, 2017 | 143.21M |
| December 31, 2016 | 112.14M |
| December 31, 2015 | 147.48M |
| December 31, 2014 | 48.57M |
| December 31, 2013 | 40.96M |
| December 31, 2012 | 64.18M |
| December 31, 2011 | 70.39M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Anika Therapeutics, Inc. | 25.77M |
| Aldeyra Therapeutics, Inc. | 25.66M |
| Repligen Corp. | 51.31M |
| AC Immune SA | 67.96M |
| Amgen, Inc. | 6.974B |